The focus of the Ophthalmic Innovation and Technology Program is currently on micro-interventional innovation, which is rapidly transforming ocular treatment. New York Eye and Ear Infirmary of Mount Sinai (NYEE) has been a leader in the field, not only as a top recruiting site of clinical trials for some of these products but also by quickly adapting them into the standard practice of care for our patients.
miLOOP Cataract Innovation: First Device for Micro-interventional Cataract Surgery
NYEE is the first hospital on the North East to introduce miLOOP (Iantech, Inc), a micro-interventional cataract fragmentation device for high-precision, non-thermal, minimally invasive cataract surgery, which greatly enhances the conventional phaco surgical technique.
Phacoemulsification, while extremely successful, has been the standard of care for 50-years. However, the technique can introduce a lot of undesirable energy and sometimes leads to corneal damage and endothelial cell loss, especially in cases of dense and large cataracts.
Borrowing from the recent advances in micro-invasive techniques in cardiovascular surgery and interventional radiology, Dr. Ianchulev and his engineering team at the company he co-founded, Iantech, Inc., developed miLOOP, a game-changing technology which for the first time allows for energy-free lens fragmentation using a pen-like micro-interventional device. The device uses advanced nitinol technology with super elastic, memory-shape micro-filament which fragments even the hardest cataracts with no ultrasonic, vibrational energy and no heat introduced into the eye. miLOOP can cut through rock-hard cataracts without rupturing the 4 micron-thin capsule enveloping the lens—this ultra-thin lenticular “envelope” makes even routine cataract surgery challenging and can lead to many complications.